A pragmatic dose-finding approach using short-term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials.

Abstract

There is a growing need for study designs that can evaluate efficacy and toxicity outcomes simultaneously in phase I or phase I/II cancer clinical trials. Many dose-finding approaches have been proposed; however, most of these approaches assume binary efficacy and toxicity outcomes, such as dose-limiting toxicity (DLT), and objective responses. DLTs are… (More)
DOI: 10.1002/pst.1590

Topics

8 Figures and Tables

Cite this paper

@article{Asakawa2013APD, title={A pragmatic dose-finding approach using short-term surrogate efficacy outcomes to evaluate binary efficacy and toxicity outcomes in phase I cancer clinical trials.}, author={Takashi Asakawa and Chikuma Hamada}, journal={Pharmaceutical statistics}, year={2013}, volume={12 5}, pages={315-27} }